

해외 바이오의약품 임상 현황 (2021.3.15~2021.3.21)

한국바이오의약품협회, 2021.3.23.  
출처: ClinicalTrials.gov

○ 미국 28건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04796896	A Study to Evaluate Safety and Effectiveness of mRNA-1273 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age	SARS-CoV-2	Biological: mRNA-1273 Biological: Placebo	ModernaTX, Inc.	Phase 2  Phase 3	
NCT04776239	Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial Dysfunction in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)	Diabetes Mellitus Ischemic Heart Disease	Drug: 100 million Allogeneic Mesenchymal Human Stem Cells Other: Placebo	Joshua M Hare National Heart, Lung, and Blood Institute (NHLBI) University of Miami	Phase 1  Phase 2	
NCT04759869	Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma	Recurrent Angioimmunoblastic T-Cell Lymphoma Recurrent Enteropathy-Associated T-Cell Lymphoma Recurrent Follicular T-Cell Lymphoma Recurrent Hepatosplenic T-Cell Lymphoma Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma Refractory Angioimmunoblastic T-Cell Lymphoma Refractory Enteropathy-Associated T-Cell Lymphoma Refractory Follicular T-Cell Lymphoma Refractory Hepatosplenic T-Cell Lymphoma Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma	Drug: Brentuximab Vedotin Biological: Pembrolizumab	Northwestern University National Cancer Institute (NCI) Merck Sharp & Dohme Corp. Seagen Inc.	Phase 2	
NCT04783415	Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma	Mantle Cell Lymphoma	Drug: Acalabrutinib Biological: Ublituximab Drug: Umbralisib	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	
NCT04753216	Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Ovarian Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Refractory Fallopian Tube Carcinoma Refractory Ovarian Carcinoma Refractory Primary Peritoneal Carcinoma	Biological: Bevacizumab Drug: Irinotecan Sucrosfate	Northwestern University psen Biopharmaceuticals	Phase 2	
NCT04616248	Radio-immunotherapy (CDX-301, Radiotherapy, CDX-1140 and Poly-ICL) for the Treatment of Unresectable or Metastatic Breast Cancer Patients	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 Unresectable Breast Carcinoma	Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Drug: Poly ICL Radiation: Radiation Therapy Biological: Recombinant Flt3 Ligand	Roswell Park Cancer Institute	Phase 1	
NCT04474847	Abatacept for the Treatment of Giant Cell Arteritis	Giant Cell Arteritis	Drug: Abatacept Drug: Placebo	University of Pennsylvania	Phase 3	
NCT04348747	Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Triple-Negative Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8	Biological: Anti-HER2/HER3 Dendritic Cell Vaccine Drug: Celecoxib Biological: Pembrolizumab Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2	
NCT04242264	Phase 2 Shigella Vaccine and Challenge	Immunisation Shigella Infection	Other: Placebo Biological: Shigella sonnei strain S3G Biological: WRSs2	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	
NCT04119830	Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer	Metastatic Colorectal Adenocarcinoma Microsatellite Stable Mismatch Repair Proficient Refractory Colorectal Adenocarcinoma Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Unresectable Colorectal Carcinoma	Biological: Pembrolizumab Other: Questionnaire Administration Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI) AIM BioPharma	Phase 2	
NCT04800822	PF-07284892 in Participants With Advanced Solid Tumors	Solid Tumor	Drug: PF-07284892 Drug: lorlatinib Drug: binimetinib Biological: cetuximab Drug: encorafenib	Pfizer	Phase 1	
NCT04793958	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSAL-10)	Advanced Colorectal Cancer Metastatic Colorectal Cancer	Drug: MRTX849 Biological: Cetuximab Drug: mFOLF0X6 Regimen Drug: FOLFIRI Regimen	Mirati Therapeutics Inc.	Phase 3	
NCT04780685	A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19	Covid19	Biological: hMSC	Stemmedica Cell Technologies, Inc. bioRASI, LLC	Phase 2	
NCT04673942	A First in Human Study of AdAPT-001 in Subjects With Refractory Solid Tumors	Solid Tumor, Adult Cancer Neoplasms	Biological: AdAPT-001	EpicentRx, Inc.	Phase 1	
NCT04776317	Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults	COVID-19	Biological: ChAdV68-S Biological: ChAdV68-S-TCE Biological: SAM-LNP-S Biological: SAM-LNP-S-TCE Other: Sodium Chloride, 0.9%	National Institute of Allergy and Infectious Diseases (NIAID) Gritstone Oncology, Inc.	Phase 1	
NCT04526834	Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma	Anaplastic Large Cell Lymphoma Peripheral T Cell Lymphoma Extranodal NK/T-cell Lymphoma Diffuse Large B Cell Lymphoma Primary Mediastinal Large B-Cell Lymphoma (PMBCL)	Drug: CD30.CAR-T	Tessa Therapeutics	Phase 1	
NCT04754945	Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis	AL Amyloidosis	Drug: Bortezomib Drug: Cyclophosphamide Drug: Dexamethasone Biological: Isatuximab	Emory University Sanofi National Cancer Institute (NCI)	Phase 1	
NCT04776018	A Study Of TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma	Relapsed and/or Refractory Multiple Myeloma (RRMM)	Drug: TAK-981 Drug: Mezagitamab Drug: Daratumumab and Hyaluronidase-fihj	Takeda	Phase 1  Phase 2	
NCT04499924	Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Adenocarcinoma	Drug: tucatinib Drug: trastuzumab Drug: ramucirumab Drug: paclitaxel Other: tucatinib placebo Other: trastuzumab placebo	Seagen Inc.	Phase 2  Phase 3	
NCT04639050	Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease	Alzheimers Disease	Drug: RO7126209 Drug: Placebo	Hoffmann-La Roche	Phase 1  Phase 2	
NCT04801420	Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Peadiatric And Adult Study Population	Lyme Borreliosis	Biological: VLA15 Biological: Placebo	Valneva Austria GmbH Pfizer	Phase 2	
NCT04799353	Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)	Human Immunodeficiency Virus (HIV)	Drug: Budigalimab Drug: Placebo	AbbVie	Phase 1	
NCT04673357	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	
NCT04660344	A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy	Muscle-invasive Bladder Cancer	Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	
NCT04552899	A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PRM-151 Drug: Placebo	Hoffmann-La Roche	Phase 3	
NCT04787991	Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	Metastatic Pancreatic Adenocarcinoma	Drug: Nivolumab (Cohort A) Drug: Ipilimumab (Cohort A and B) Drug: Hydroxychloroquine (HCQ) (Cohort B) Drug: Nab-paclitaxel (nP) (Cohort A and B) Drug: Gemcitabine (gem) (Cohort A and B)	Parker Institute for Cancer Immunotherapy Bristol-Myers Squibb Cancer Research Institute, New York City	Phase 1	
NCT04788511	Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity	Obesity	Drug: Semaglutide Drug: Placebo (semaglutide)	Novo Nordisk A/S	Phase 3	

해외 바이오의약품 임상 현황 (2021.3.15~2021.3.21)

한국바이오의약품협회, 2021.3.23.  
출처: ClinicalTrials.gov

○ 영국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04607850	Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions	HPV	Biological: ChAdOx1-HPV Biological: MVA-HPV Biological: Placebo	Vaccitech Limited	Phase 1 Phase 2	---
NCT04788511	Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity	Obesity	Drug: Semaglutide Drug: Placebo (semaglutide)	Novo Nordisk A/S	Phase 3	---
NCT04660344	A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy	Muscle-invasive Bladder Cancer	Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	---
NCT04552899	A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PRM-151 Drug: Placebo	Hoffmann-La Roche	Phase 3	---
NCT04673357	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	---
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	---

○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04660344	A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy	Muscle-invasive Bladder Cancer	Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	---
NCT04552899	A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PRM-151 Drug: Placebo	Hoffmann-La Roche	Phase 3	---

○ 독일 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04660344	A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy	Muscle-invasive Bladder Cancer	Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	---
NCT04552899	A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PRM-151 Drug: Placebo	Hoffmann-La Roche	Phase 3	---
NCT04673357	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	---
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	---

○ 중국 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04590118	Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)	Ischemic Stroke	Drug: it-hMSC Drug: Placebo	Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd Beijing Tiantan Hospital	Phase 1 Phase 2	---
NCT04800133	Covid-19 Vaccination in Adolescents	Covid19	Biological: Tozinameran Biological: Oxford-AstraZeneca COVID-19 vaccine Biological: CoronaVac	The University of Hong Kong	Phase 3	---
NCT04795128	A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy	Hematologic Malignancy	Biological: IBI322	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1	---
NCT04782765	Phase II Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma	Disease-free Survival Rate	Drug: Camrelizumab+Chemotherapy+Chemoradiotherapy	Tianjin Medical University Cancer Institute and Hospital	Phase 2	---
NCT04684472	Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies	Refractory B-Cell Non-Hodgkin Lymphoma Refractory Leukemia	Biological: Modified anti-CD19 CAR T cells	Liquan Zou Sichuan University	Phase 1	---
NCT04661150	A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction	Gastric Cancer Gastroesophageal Junction Adenocarcinoma	Drug: Atezolizumab Drug: Trastuzumab Drug: Capecitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 2	---
NCT04660344	A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy	Muscle-invasive Bladder Cancer	Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	---
NCT04552899	A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PRM-151 Drug: Placebo	Hoffmann-La Roche	Phase 3	---

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04673357	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: Ustekinumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	---
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	---
NCT04660344	A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy	Muscle-invasive Bladder Cancer	Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	---